NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

Shareholders of Durham-based BioCryst Pharmaceuticals have rejected a January 2018 merger agreement with Pennsylvania-based Idera Pharmaceuticals, in a special vote that will keep BioCryst in the Triangle.
KeraNetics of Winston-Salem has reached a merger agreement with Microchips Biotech of Lexington, Mass., to create a new company, Keratin Biosciences.
Xeomin, a botulinum toxin similar to Botox that is used cosmetically to smooth frown lines between the eyebrows, is becoming an ever more versatile product for Raleigh-based Merz North America. The FDA just approved it to treat chronic sialorrhea, or excessive drooling, in adults. 
A new study conducted by researchers from Duke University, MIT and Singapore’s Nanyang Technological University shows that sound waves are capable of rapidly and efficiently separating circulating tumor cells (CTCs) from blood.
Durham-based genome editing company Precision BioSciences announced that it has raised $110 million to further the development of its proprietary ARCUS genome editing platform.
Istari Oncology, a young Research Triangle Park biotechnology company started by a world-famous Duke University brain cancer team, has reported rare positive results in a Phase 1 clinical trial of its experimental treatment for glioblastoma.
Even the best scientific innovation can be flattened by public distrust. That was the major reminder from Kevin Folta, Ph.D., a professor of horticultural sciences at the University of Florida, to dozens of people gathered at the North Carolina Biotechnology Center Wednesday. 
North Carolina’s global precision health and gene therapy profile got a boost this week with the announcement that Swiss drug giant Roche will add $2.4 billion to the $1 billion it already invested, to buy gene testing company Foundation Medicine.
A British company with U.S. headquarters in Research Triangle Park has become the first to receive U.S. Food and Drug Administration approval for a prescription drug derived from marijuana.
Startups, small businesses and incubators developing solutions for health security needs are invited to a U.S. Department of Health and Human Services pre-proposal Webex conference call on Friday, June 22, at First Flight Venture Center in Research Triangle Park. 
Glenmark Pharmaceuticals, an India-based global pharmaceutical company, has received its first U.S. Food and Drug Administration go-ahead to market one of its North Carolina-made drugs in the United States.
​​​​​​​Chiesi USA of Cary and its European partner Holostem Terapie Avanzate have received Orphan Drug Designation from the U.S. Food and Drug Administration for an investigational cell-based therapy for a rare eye disease.
Morrisville-based Humacyte, developer of a bioengineered blood vessel, has formed a global partnership with Fresenius Medical Care, the world's largest provider of dialysis products and services, and will receive a $150 million equity investment as part of the deal.



NCBiotech's RTP office closed at 2 p.m. on Monday, March 12 due to winter weather conditions. Many of us may still be working remotely, so please try us on email.

On Tuesday, the RTP office will open at 10 a.m.

Chimerix, a Durham-based biopharmaceutical company that’s developing novel antiviral medicines for unmet medical needs, has received Orphan Drug Designation from the U.S. Food and Drug Administration for brincidofovir, its smallpox treatment.
scroll back to top of page